5-MeO-DMT was first [[Organic synthesis|synthesized]] in 1936, and in 1959 it was isolated as one of the [[Psychoactive drug|psychoactive]] ingredients of ''[[Anadenanthera peregrina]]'' [[seed]]s used in preparing [[Anadenanthera peregrina|Yopo]] snuff. It was once believed to be a major component of the psychoactive [[neuropsychopharmacology|effects]] of the snuff, although this has recently been shown to be unlikely, due to the limited or sometimes even non-existent quantity contained within the seeds, which instead achieve their psychoactivity from the ''O''-[[Demethylation|demethylated]] [[metabolite]] of 5-MeO-DMT, [[bufotenin]].<ref>{{cite journal|first1=Jonathan|last1=Ott|title=Pharmañopo—Psychonautics: Human Intranasal, Sublingual, Intrarectal, Pulmonary and Oral Pharmacology of Bufotenine|url=http://www.tandfonline.com/doi/abs/10.1080/02791072.2001.10400574|journal=Journal of Psychoactive Drugs|date=July–September 2001|issn=0279-1072|pages=273–281|volume=33|issue=3|pmid=11718320|doi=10.1080/02791072.2001.10400574}}</ref><ref name=Shen/> It is [[metabolism|metabolized]] mainly by [[CYP2D6]].<ref name=Shen>{{cite journal|first1=Hong-Wu|last1=Shen|first2=Xi-Ling|last2=Jiang|first3=Jerrold C.|last3=Winter|first4=Ai-Ming|last4=Yu|title=Psychedelic 5-Methoxy-''N'',''N''-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions|journal=Current Drug Metabolism|date=October 2010|issn=1389-2002|pages=659–666|volume=11|issue=8|pmid=20942780|pmc=3028383|doi=10.2174/138920010794233495}}</ref>

 
5-MeO-DMT is a [[Methoxylation|methoxylated]] [[derivative (chemistry)|derivative]] of [[Dimethyltryptamine|DMT]]. Its [[pharmacology|pharmacological]] [[pharmacological activity|action]] is mainly through [[5-HT receptor|serotonin receptors]]. Specifically, it shows high [[Affinity (pharmacology)|affinity]] for the [[5-HT2 receptor|5-HT<sub>2</sub>]] and [[5-HT1A receptor|5-HT<sub>1A</sub>]] subtypes.<ref>{{cite journal|first1=Kirsten|last1=Krebs-Thomson|first2=ErbertM.|last2=Ruiz|first3=Virginia|last3=Masten|first4=Mahalah|last4=Buell|title=The roles of 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats|url=https://link.springer.com/article/10.1007/s00213-006-0566-1|journal=Psychopharmacology|date=December 2006|issn=0033-3158|pages=319–329|volume=189|issue=3|doi=10.1007/s00213-006-0566-1|pmid=17013638|first5=MarkA.|last5=Geyer}}</ref>

 
Additional [[mechanism of action|mechanisms of action]] such as [[reuptake inhibitor|inhibition]] of [[monoamine]] [[reuptake]] may be involved also.<ref>{{cite journal|first1=Fumiko|last1=Nagai|first2=Ryouichi|last2=Nonaka|first3=Kanako|last3=Satoh Hisashi Kamimura|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|url=http://www.sciencedirect.com/science/article/pii/S0014299906013811|journal=European Journal of Pharmacology|date=22 March 2007|pages=132–137|volume=559|issue=2–3|doi=10.1016/j.ejphar.2006.11.075|pmid=17223101}}</ref>
